Seizure exacerbation and status epileptics related to carbamazepine‐10,11‐epoxide

Elson L. So, Kevin H. Ruggles, Gregory D. Cascino, Peter A. Ahmann, Karen W. Weatherford

Research output: Contribution to journalArticle

62 Scopus citations

Abstract

Over a 3‐year period, we encountered 6 adults whose seizure control unexpectedly deteriorated with the occurrence of partial status epilepticus and daily multiple seizures. Analysis of the case histories and subsequent clinical follow‐up for 1 1/2 to 3 years disclosed the following evidence that demonstrates the role of carbamazepine‐epoxide in the development of the seizure exacerbation: (1) There were high serum carbamazepine‐epoxide concentrations while serum carbamazepine concentrations were lower than or the same as baseline levels; (2) all patients were taking drugs that are known to increase serum carbamazepine‐epoxide concentrations; (3) status epilepticus failed to respond to intravenous phenytoin loading; (4) seizure exacerbation in all patients was corrected by withholding carbamazepine dose; (5) seizure exacerbation recurred in 1 patient who resumed the same dose of carbamazepine; and (6) there were no prior status epilepticus or daily multiple seizures despite previous toxicities with other antiepileptic drugs in 3 patients. Our experience shows that inconspicuous elevation of carbamazepine‐epoxide levels during polytherapy may precipitate a distinct state of drug toxicity characterized by severe exacerbation of seizures. Mental retardation may be a predisposition to this condition.

Original languageEnglish (US)
Pages (from-to)743-746
Number of pages4
JournalAnnals of neurology
Volume35
Issue number6
DOIs
StatePublished - Jun 1994

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Seizure exacerbation and status epileptics related to carbamazepine‐10,11‐epoxide'. Together they form a unique fingerprint.

  • Cite this